Potential of liraglutide (Victoza) in multifactor treatment approach in type 2 diabetes mellitus

To study the efficacy of treatment with liraglutide in women with type 2 DM and NAFLD. A group of 10 women with type 2 DM and obesity, with T2DM duration 6 months - 2 years, drug naïve or getting 1000-2500 gr metformin for at least 6 months with ultrasound markers of fatty liver and elevated ALT without hepatic insufficiency. Weight, BMI, HbA1C, ALT, AST, hepatic elasticity were measured before liraglutide 1.2 mg daily and 6 month after treatment. We got significant reduction of weight, BMI, HbA1C, in all treated women. In 7 women ALT level normalization was seen, in 3 women - ALT level reduction by 43, 37, 40% respectively. In 5 patients with initial fibrosis elasticity normalization was seen. In 1 - decrease of fibrosis degree and only in 1 - no improvement. Liraglutide in women with T2DM and NAFLD for 6 month helps to achieve weight, BMI, HbA1C reduction as well as elevated ALT normalization and hepatic fibrosis decrease.